SMAD4 (SMAD Family Member 4) is the central co-mediator of TGF-beta signaling in the nervous system. This protein partners with receptor-regulated SMADs (SMAD2, SMAD3) to transduce TGF-beta signals from the cell surface to the nucleus, regulating gene expression programs that control neuroinflammation, neuronal survival, and synaptic plasticity.
SMAD4 (also known as DPC4 - Deleted in Pancreatic Cancer 4) is a 552 amino acid protein that serves as the central mediator of canonical TGF-beta signaling[1]. Unlike other SMADs, SMAD4 is not a direct substrate of TGF-beta receptors; instead, it forms heteromeric complexes with phosphorylated SMAD2/SMAD3 to regulate transcription of target genes[2].
| Attribute | Value |
|---|---|
| Protein Name | SMAD4 |
| Gene Symbol | SMAD4 |
| UniProt ID | Q99707 |
| Molecular Weight | 60 kDa |
| Protein Length | 552 amino acids |
| PDB Structures | 1G1J, 1GGK, 1MR1, 1O7W, 2FLB |
| Subcellular Localization | Cytoplasm, nucleus (upon signaling) |
The study of Smad4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Massague J. TGF-beta signal transduction. Annu Rev Biochem. 2000;69:137-163. ↩︎
Heldin CH, et al. TGF-beta signaling mechanisms. EMBO J. 2021;40(10):e106013. ↩︎
Brionne TC, et al. Loss of TGF-beta signaling in neurons. J Neurosci. 2021;41(9):1857-1872. ↩︎
Kane CJ, et al. TGF-beta neuroprotection in PD. Mol Neurodegener. 2018;13(1):54. ↩︎
Ferguson L, et al. TGF-beta and synaptic plasticity. Hippocampus. 2019;29(11):1021-1035. ↩︎
Wrana JL, et al. Smad4 transcriptional regulation. Genes Dev. 2019;33(15-16):981-994. ↩︎
Caraci F, et al. TGF-beta alterations in AD. J Alzheimers Dis. 2021;80(2):503-518. ↩︎
Wyss-Coray T, et al. TGF-beta and APP processing. Nat Neurosci. 2020;23(10):1183-1194. ↩︎
Tolar M, et al. TGF-beta and neuroinflammation in AD. Nat Rev Neurol. 2020;16(8):431-446. ↩︎
Rai SN, et al. TGF-beta protection in dopaminergic neurons. Redox Biol. 2022;51:102281. ↩︎
Tong J, et al. SMAD4 in PD. Mov Disord. 2019;34(11):1644-1653. ↩︎
Dormann D, et al. TGF-beta in ALS. Brain. 2020;143(7):2011-2026. ↩︎
Ilieva H, et al. TGF-beta pathway in ALS. Lancet Neurol. 2019;18(10):918-929. ↩︎
Akhurst RJ, et al. TGF-beta modulators. Nat Rev Drug Discov. 2021;20(7):551-569. ↩︎
Sakauchi M, et al. TGF-beta agonists. Neuropharmacology. 2021;198:108765. ↩︎